Chronic Pulmonary Hypertension Epidemiology

Chronic Pulmonary Hypertension (CPH) Insights and Trends

• CPH is more prevalent in regions with higher burden of underlying conditions such as chronic heart and lung diseases, thromboembolic disorders, aging populations, and increasing exposure to environmental risk factors, all of which contribute to disease onset and progression.
• Females experience a higher disease burden and earlier onset of CPH compared to males, likely due to hormonal influences, genetic susceptibility, and differences in vascular biology.
• Rising prevalence of cardiopulmonary diseases, aging populations, and improved diagnostic awareness are expected to drive the global burden of CPH over the next decade, highlighting the need for early detection, better risk stratification, and expanded access to effective therapies.

Chronic Pulmonary Hypertension (CPH) Epidemiology Forecast in the 7 MM

• 2025 Prevalent Cases of CPH: ~XXXX million
• CPH Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Chronic Pulmonary Hypertension (CPH) Epidemiology Forecast - 2036’ report delivers an in-depth understanding of the CPH, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chronic Pulmonary Hypertension (CPH) Understanding and Diagnosis Algorithm

Chronic Pulmonary Hypertension Overview

Chronic Pulmonary Hypertension is a progressive cardiovascular condition characterized by persistently elevated pressure in the pulmonary arteries, leading to increased strain on the right side of the heart and impaired blood flow through the lungs. It can range from mild to severe, with symptoms such as shortness of breath, fatigue, chest discomfort, and syncope, particularly in advanced stages. CPH is primarily caused by underlying conditions such as chronic lung diseases, left heart disorders, recurrent pulmonary embolism, or idiopathic vascular remodeling. Diagnosis is based on imaging, echocardiography, and confirmatory right heart catheterization. 

Chronic Pulmonary Hypertension Diagnosis

Chronic Pulmonary Hypertension (CPH) is diagnosed through clinical evaluation and imaging, often suspected in patients with unexplained breathlessness and fatigue. Echocardiography is the primary screening tool to estimate pulmonary artery pressure and assess heart function. Confirmation is done by right heart catheterization, which directly measures pulmonary pressures. Additional tests such as ECG, chest X-ray, and CT or V/Q scan help identify underlying causes. 

Further details are provided in the report.

Chronic Pulmonary Hypertension (CPH) Epidemiology

Key Findings from CPH Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, the total prevalent cases of CPH in the 7MM were approximately XXXX million in 2025.
• The observed female predominance and earlier onset of CPH highlight the importance of gender-specific risk assessment, early screening, and tailored management strategies to improve clinical outcomes. 
• The CPH prevalent cases were segmented based on age in four age‐groups <45 years, 45-54 years, 55-64 years, 65 years and above. Our estimate suggests that in the US highest number of cases were in the age group 65 years and above and the least in <45 years in 2025.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of CPH, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Chronic Pulmonary Hypertension (CPH) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of CPH? What will be the growth opportunities across the 7MM concerning the patient population with CPH?
• What is the historical and forecasted CPH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.